Octavio Espinoza, Chief Financial Officer at LIGAND PHARMACEUTICALS INC (LGND), sold 26,846 shares at $198.71 ($5.5M) on 2026-03-04, disclosed to the SEC on 2026-03-06.
Open-market sale of $5.5M LGND by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $198.71 | 699 | $139K | 2.5% |
| 2 | $198.71 | 699 | $139K | 2.5% |
| 3 | $200.08 | 53 | $11K | 0.2% |
| 4 | $200.08 | 53 | $11K | 0.2% |
| 5 | $201.09 | 698 | $140K | 2.5% |
| 6 | $201.09 | 698 |
| $140K |
| 2.5% |
| 7 | $201.73 | 950 | $192K | 3.5% |
| 8 | $201.73 | 950 | $192K | 3.5% |
| 9 | $202.79 | 697 | $141K | 2.6% |
| 10 | $202.79 | 697 | $141K | 2.6% |
| 11 | $203.63 | 668 | $136K | 2.5% |
| 12 | $203.63 | 668 | $136K | 2.5% |
| 13 | $204.74 | 743 | $152K | 2.8% |
| 14 | $204.74 | 743 | $152K | 2.8% |
| 15 | $205.79 | 1,457 | $300K | 5.4% |
| 16 | $205.79 | 1,457 | $300K | 5.4% |
| 17 | $206.89 | 1,588 | $329K | 5.9% |
| 18 | $206.89 | 1,588 | $329K | 5.9% |
| 19 | $207.91 | 2,457 | $511K | 9.2% |
| 20 | $207.91 | 2,457 | $511K | 9.2% |
| 21 | $208.80 | 3,413 | $713K | 12.9% |
| 22 | $208.80 | 3,413 | $713K | 12.9% |
| Total | $205.83 avg | 26,846 | $5.5M | 100% |
| Filing → |
| LGND | SELL | 2025-12-16 | $679K | — | Filing → |
| LGND | BUY | 2025-05-13 | $156K | — | Filing → |
| LGND | SELL | 2025-03-06 | $575K | — | Filing → |